Therapeutic Insights
Filter News
Found 750 articles
-
Ferring Announces New Collaboration for Development of Olamkicept
6/9/2022
Strategic collaboration to further develop olamkicept highlights Ferring’s continued commitment to innovation in gastroenterology and inflammatory bowel disease.
-
Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference
6/7/2022
Alzheon, Inc. announced that it will be presenting at the 4th International Trisomy 21 Research Society Conference to be held on June 9-12, 2022 in Long Beach, California, USA.
-
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
6/3/2022
Todos Medical, Ltd. (OTCQB: TOMDF) , a comprehensive medical diagnostics and related solutions company, today announced that its academic partner, Dr. Thomas Arendt at Leipzig University, has completed full enrollment for 2nd cohort (confirmatory) for the ongoing clinical trial to evaluate the concordance of the LymPro Alzheimer’s Blood Test scores with amyloid PET imaging scores.
-
Cassava Sciences is reeling after another journal retracted an article co-authored by a key collaborator on its experimental Alzheimer's disease therapeutic, simufilam.
-
Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development
6/2/2022
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company has recently closed an extension of its Series B funding round, raising $2.7 million.
-
A largely untested and unproven treatment for Alzheimer’s disease, called transcranial pulse stimulation (TPS), is becoming popular around the world, although experts are skeptical.
-
GNS and the Global Alzheimer's Platform Foundation® Partner to advance Alzheimer's R&D
6/1/2022
3-year partnership will leverage biomarker database and AI for innovation to create "Digital Twins" that help uncover the complex biology driving Alzheimer's Disease.
-
Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Program For Alzheimer’s Disease Treatment, AD101
6/1/2022
Societal CDMO, Inc. announced that it has been selected by AmyriAD Pharma to provide CDMO services to support the ongoing clinical development of AD101.
-
Six Things People Living with Alzheimer's Disease and Other Dementia Want You to Know
6/1/2022
Many Americans struggle with what to say and do when a family member, friend, co-worker or neighbor is diagnosed with Alzheimer's disease or another dementia.
-
Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial
6/1/2022
TauRx Pharmaceuticals Ltd, the global leader in tau-based research in Alzheimer's, announced unblinding of initial data from completion of the randomised portion of their pivotal Phase 3 clinical trial, LUCIDITY.
-
Although there are many mechanisms proposed that contribute to neuroinflammation and damage caused by inflammaging in the brain, INmune Bio has focused on tumor necrosis factor (TNF).
-
NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update
5/31/2022
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.
-
Telo Genomics Announces Successful Validation of Its Proprietary Automation Tools for Smoldering Multiple Myeloma
5/31/2022
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has completed the validation of a suite of proprietary automation tools developed using cutting-edge machine learning, deep machine learning and artificial intelligence technologies to maximize the efficiency and throughput of its technology workflow.
-
Biomind Labs Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease
5/26/2022
Biomind Labs Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease.
-
AlzeCure Presents at Redeye Growth Day on June 2
5/25/2022
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company will participate at Redeye Growth Day on June 2, 2022 at 09:10 CEST.
-
Pfizer and Eli Lilly are forging ahead with ulcerative colitis (UC) research after posting positive results from their respective Phase III studies.
-
A blood test to diagnose Alzheimer’s disease launched in April by Quest Diagnostics has the potential to screen patients for risk years before symptoms appear.
-
Iterative Scopes DDW Presentation Shows Accuracy of Automated Endoscopic Disease Scoring Model, With Potential to Accelerate IBD Clinical Trials
5/24/2022
Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced today that data presented at Digestive Disease Week (DDW) 2022 show that the company’s proprietary machine learning model accurately and consistently predicts scoring of endoscopic disease severity in ulcerative colitis (UC), a common type of inflammatory bowel disease (IBD).
-
Alzinova initiates development of a stable cell line to prepare the monoclonal antibody ALZ-201 for Alzheimer's clinical trials
5/24/2022
Alzinova AB announces the initiation of the next step in the preclinical development of its oligomer-specific monoclonal antibody, ALZ-201.
-
Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer’s Disease
5/18/2022
Karuna Therapeutics, Inc. announced that it will host a virtual event on Wednesday, May 25, 2022, at 8:00 a.m. ET.